文献速递特殊人群用药药物不良反应与药物警戒

马萨诸塞州医疗补助计划中孕酮使用与出生结局评估

Evaluation of Progesterone Utilization and Birth Outcomes in a State Medicaid Plan.
PubMed 文献 · Pharmacotherapy · 2017-09-28

该回顾性队列研究利用2011至2015年马萨诸塞州医疗补助成员的医疗索赔、药房索赔和事先授权数据,评估孕酮使用者的出生结局和用药依从性。190名符合条件者中169人配药,62.1%足月分娩,平均依从性PDC为0.79,66.3%达到PDC≥0.8。结论认为尽管出生结局与临床试验相似,但用药依从性低,可能需要依从性支持。

要点

  • 62.1%的孕酮使用者实现足月分娩(37周妊娠),与临床试验效果一致。
  • 66.3%的成员依从性良好(PDC≥0.8),总体平均PDC为0.79。
  • 有既往分娩孕周数据的成员中,两次妊娠孕周平均差为8.25周(SD=6.11)。

核心结论

  • 尽管出生结局与临床试验和全国趋势相似,但该州医疗补助计划中孕酮用药依从性较低,成员可能从依从性支持中获益。

研究设计与样本

  • 回顾性队列研究,使用2011年1月1日至2015年3月31日期间提交孕酮事先授权申请的MassHealth成员的医疗索赔、药房索赔和事先授权数据。
  • 共筛选418名成员,190名符合纳入标准,169名配取了孕酮。
  • 排除标准包括保险覆盖中断、孕酮未用于预防早产、当前孕周或分娩日期不可用。

主要发现

  • 平均年龄29.2岁(SD=5.23),90.5%的成员存在临床合并症。
  • 62.1%的成员足月分娩(37周妊娠)。
  • 在有既往分娩孕周数据的成员中,两次妊娠孕周平均差为8.25周(SD=6.11)。
  • 66.3%的成员依从性良好(PDC≥0.8),总体平均PDC为0.79(SD=0.26)。

临床怎么用

  • 对于使用孕酮预防早产的医疗补助成员,应关注用药依从性并考虑提供依从性支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Progesterone (hydroxyprogesterone caproate injection and vaginal progesterone) has been shown to reduce preterm birth (PTB) rates by a third among pregnant women at high risk. The purpose of this analysis is to report birth outcomes and medication adherence among Massachusetts Medicaid (MassHealth) members receiving progesterone, evaluate the association between member characteristics and birth outcomes and medication adherence, and compare cost of care with a prior preterm pregnancy. METHODS: This retrospective cohort study used medical claims, pharmacy claims, and prior authorization (PA) request data for MassHealth members who had a PA submitted for progesterone between January 1, 2011, and March 31, 2015. Members were excluded due to breaks in coverage, progesterone was not indicated for prevention of PTB, and if current gestational week or date of delivery was unavailable. MAIN RESULTS: A total of 418 members were screened for inclusion of whom 190 met criteria and 169 filled progesterone. Mean age was 29.2 years (SD = 5.23), and clinical comorbidities were identified in 90.5% of members. Consistent with clinical trials on progesterone effectiveness, 62.1% of members had a term delivery (37 wks of gestation). Among members with prior gestational age at delivery available, the average difference in gestational age between pregnancies was 8.25 weeks (SD = 6.11). In addition, 66.3% of members were adherent to progesterone based on proportion of days covered (PDC) of 0.8 or higher. The overall mean PDC was 0.79 (SD = 0.26). CONCLUSION: Despite similar birth outcomes in clinical trials and national trends, medication adherence is low in this state Medicaid program. Therefore, members may benefit from adherence support.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Hydery T, Price MK, Greenwood BC, et al. Evaluation of Progesterone Utilization and Birth Outcomes in a State Medicaid Plan. Pharmacotherapy. 2017. PMID: 28833362. doi:10.1002/phar.2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。